Press releases

24 Sep 2024

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

23 Sep 2024

UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis

9 Sep 2024

New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease

6 Sep 2024

Transparency notification BlackRock, Inc.

6 Sep 2024

UCB presents new data across expansive epilepsies portfolio at 15th European Epilepsy Congress (EEC)

5 Sep 2024

Transparency notification BlackRock, Inc.

Press releases

Press releases

Search Press releases

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis

New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease

Transparency notification BlackRock, Inc.

UCB presents new data across expansive epilepsies portfolio at 15th European Epilepsy Congress (EEC)

Transparency notification BlackRock, Inc.

Choose a Country

UCB Belgium: A global hub of healthcare innovation

Publications - A dedicated space where we share a collection of our scientific peer-reviewed...

Pipeline - Check out our clinical development pipeline spanning several therapy areas

Hidradenitis Suppurativa – Learn more about Hidradenitis Suppurativa an inflammatory skin disease

WoCBA - Closing the gaps in research in the care of women of childbearing age with chronic diseases

Clinical studies – Click to find out more on our clinical studies

Sustainability – Click here to learn more about our sustainable approach

UCBCares® - Discover what UCBCares® is about and the services they offer

Advancing Our Gene Therapy Journey

UCB receives U.S. FDA approval for BIMZELX[®] (bimekizumab-bkzx) as the first IL-17A and IL-17F...

Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant...

UCB completes sale of established brands and updates 2024 financial guidance

UCB completes sale of established brands and updates 2024 financial guidance

Half-year results 2024: strong start into UCB’s decade of growth

Download center – Click here to view a collection of useful documents

Press releases

Search Press releases

UCB and Biogen Announce Positive Topline Results From Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus and are Initiating Second Phase 3 Study in 2024

UCB announces U.S. FDA approvals for BIMZELX[®] (bimekizumab-bkzx) for the treatment of psoriatic arthritis, non-radiographic axial spondyloarthritis and ankylosing spondylitis

New insights highlight unmet needs for people living with Lennox-Gastaut syndrome and significant burden of the disease

Transparency notification BlackRock, Inc.

UCB presents new data across expansive epilepsies portfolio at 15th European Epilepsy Congress (EEC)

Transparency notification BlackRock, Inc.

Choose a Country